Connect with us

CBD News

GW Pharmaceuticals Records $72 Million Revenue for the Sale of CBD Drug Epidiolex

Denis Mariti

Published

on

GW Pharmaceuticals Records $72 Million Revenue for the Sale of CBD Drug Epidiolex
- Ad -

Epidiolex – the only federally approved CBD Product in the U.S. – has recorded a strong patient interest, which helped drug maker GW Pharmaceuticals hit $72 million in revenue last quarter.

Epidiolex was launched last November after approval by the FDA to control seizures.

GW Pharma reported that Epidiolex sales for the quarter ending in June were $68.4 million, and said that the drug had been used by over 12,000 patients coming from 2,500 physicians since it was launched.

Executives of this London-based company attributes Epidiolex’s strong start to “pent-up demand” for regulated CBD treatment. The company also noted that it has been seeing more adults than projected signing up to get the medication.

GW Pharma highlighted its interests in seizing Europe’s big market.

Last week, the Medicinal Products for Human Use committee of the European Medicine Agency approved Epidiolex. A final decision is expected by the end of this fall.

GW Pharma made $80 million last quarter, which translates to 21 cents per share, with a revenue of $72 million. One year ago, before the launch of Epidiolex, the company lost $84 million.

GW CEO Justin Gover cautioned investors that the cannabis treatment novelty will not last forever and that both doctor and patient’s interest will get back to normal in future quarters.

Denis is one of the most experienced researchers for reviews we have with years of experience in writing about CBD products. He will be one of the most viewed authors due to his own thrill in sharing what he is learning about cannabidiol and supplement use. With a goal of providing clarity within the budding CBD oil industry, Denis will be spending much of the year going through a catalogue of cannabis oil companies in the near future.

Continue Reading

Ultimate CBD Guide


Disclaimer

ultimate-cbd-products-company-guidepopular-cbd-health-benefits best-cannabidiol-guide-resources hemp guide

TimesofCBD is the most active daily CBD news publication featuring the latest cannabis industry stories and marijuana market trends. As the leader in CBD-centric content curation, we invite all readers to come for the headlines and stay for the insights. Quality is the top priority when presenting user guides, analyzing product reviews and reporting fact-checked news announcements. All information is for educational and informational purposes only. Disclaimer.

Got news? Email contact@timesofcbd.com